Previous 10 | Next 10 |
Celldex Therapeutics Inc. (NASDAQ:CLDX) traded today at a new 52-week high of $47.63. This new high was reached on below average trading volume as 523,000 shares traded hands, while the average 30-day volume is approximately 1.3 million shares. There is potential upside of 10.6% for shar...
Earnings remained a substantial mover during Wednesday's midday action. Camping World (NYSE:CWH) and Global Blood Therapeutics (NASDAQ:GBT) both rallied on their respective quarterly reports. Meanwhile, the release of disappointing results sparked declines in shares of Office Depot (NASDAQ:OD...
Celldex Therapeutics (NASDAQ: CLDX) recently announced results from a phase 1b clinical study evaluating CDX-0159 in treating two of the most common forms of chronic inducible hives. In this Motley Fool Live video recorded on July 14, 2021 , Motley Fool contributors Keith Sp...
Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...
naphtalina/iStock via Getty Images Celldex Therapeutics (CLDX) has risen ~2.0% in the pre-market after Guggenheim Securities initiated its coverage with a buy recommendation highlighting the potential of CDX-0159 company’s experimental therapy that targets a range of skin dis...
HAMPTON, N.J., July 16, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 6,845,238 shares of its common stock, which includes th...
Shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) traded today at $46.38, eclipsing its 52-week high. So far today approximately 523,000 shares have been exchanged, as compared to an average 30-day volume of 1 million shares. Over the past year, Celldex Therapeutics Inc. has traded in a ...
Celldex Therapeutics (CLDX) has priced its public offering of 5,952,381 common shares at $42.00/share, for expected gross proceeds of ~$250M.Underwriters' over-allotment is an additional 892,857 shares. Net proceeds will be used to continue clinical and preclinical development of its product ...
HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per...
Shares of Celldex Therapeutics (NASDAQ: CLDX) were jumping 10.8% higher as of 3:10 p.m. EDT on Tuesday. This marked the second day of big gains for the stock. Celldex's shares skyrocketed on Monday on the company's positive results from a phase 1b study evaluating CDX-0159 in tr...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...